Epstein Secrets

50 - currently at 861.00 down 2.3% from purchase please advise thank you Richard Kahn HBRK Associates Inc. Begin forwarded message: From: "Ens, Amanda" Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pricing

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

rently at 861.00 down 2.3% from purchase please advise thank you Richard Kahn HBRK Associates Inc. tee= fa Begin forwarded message: From: "Ens, Amanda" < Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pricin

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Co

ard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York NY 10022 tel fax cell Begin forwarded message: EFTA00665656 From: "Ens, Amanda" < Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn c > Rich, With yesterday's weakness in healthcare on pr

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop